688266 泽璟制药
已收盘 07-25 15:00:00
资讯
新帖
简况
泽璟制药-U跌5.13% 资金流出叠加板块波动
智选洞察 · 07-25 05:02
泽璟制药-U跌5.13% 资金流出叠加板块波动
5款创新药纳入突破性疗法,来自宝济药业、泽璟制药等
制药网 · 07-25 02:18
5款创新药纳入突破性疗法,来自宝济药业、泽璟制药等
新事丨罗氏终止TIGIT全部三期临床
健识局 · 07-24 12:30
新事丨罗氏终止TIGIT全部三期临床
券商资管系公募,排名来了!
中国基金报 · 07-22
券商资管系公募,排名来了!
泽璟制药-U下跌5.02% 盐酸吉卡昔替尼片进展与资金流出共振
智选洞察 · 07-21
泽璟制药-U下跌5.02% 盐酸吉卡昔替尼片进展与资金流出共振
泽璟制药公布国际专利申请:“取代桥环类抑制剂及其制备方法和应用”
证券之星 · 07-18
泽璟制药公布国际专利申请:“取代桥环类抑制剂及其制备方法和应用”
广发基金吴兴武旗下广发保健A中报最新持仓,重仓泽璟制药
证券之星 · 07-18
广发基金吴兴武旗下广发保健A中报最新持仓,重仓泽璟制药
细胞免疫治疗概念盘中拉升,博济医药涨12.63%
市场透视 · 07-17
细胞免疫治疗概念盘中拉升,博济医药涨12.63%
泽璟制药-U股价回落至127元 创新药板块热度持续
金融界 · 07-16
泽璟制药-U股价回落至127元 创新药板块热度持续
中证1000医药卫生指数报12486.30点,前十大权重包含昭衍新药等
金融界 · 07-16
中证1000医药卫生指数报12486.30点,前十大权重包含昭衍新药等
科创成长层改革推进 券商系统升级及风险揭示书签署有序展开
DoNews · 07-16
科创成长层改革推进 券商系统升级及风险揭示书签署有序展开
东吴证券:首次覆盖泽璟制药给予买入评级
证券之星 · 07-14
东吴证券:首次覆盖泽璟制药给予买入评级
泽璟制药-U涨5.02% 盐酸吉卡昔替尼片新药申请进展及ASCO年会临床数据披露
智选洞察 · 07-14
泽璟制药-U涨5.02% 盐酸吉卡昔替尼片新药申请进展及ASCO年会临床数据披露
中国创新药:出海黄金时代 游到海水变蓝
中信建投证券 · 07-11
中国创新药:出海黄金时代 游到海水变蓝
泽璟制药:注射用ZG006纳入突破性治疗品种公示名单
证券之星 · 07-10
泽璟制药:注射用ZG006纳入突破性治疗品种公示名单
泽璟制药-U股价报112.60元 科创板百元股医药板块占8席
金融界 · 07-08
泽璟制药-U股价报112.60元 科创板百元股医药板块占8席
肿瘤治疗概念盘中拉升,广生堂涨15.82%
市场透视 · 07-07
肿瘤治疗概念盘中拉升,广生堂涨15.82%
泽璟制药-U涨5.34% 利好催化与资金博弈共振
智选洞察 · 07-07
泽璟制药-U涨5.34% 利好催化与资金博弈共振
泽璟制药:截至2025年3月31日公司股东户数为7,533户
证券之星 · 07-03
泽璟制药:截至2025年3月31日公司股东户数为7,533户
泽璟制药-U涨5.11%创短期新高 资金博弈与事件驱动共振
智选洞察 · 07-01
泽璟制药-U涨5.11%创短期新高 资金博弈与事件驱动共振
加载更多
公司概况
公司名称:
苏州泽璟生物制药股份有限公司
所属行业:
医药制造业
上市日期:
2020-01-23
主营业务:
苏州泽璟生物制药股份有限公司的主营业务是化学新药及生物新药的研发、生产及销售。公司的主要产品是药品。
发行价格:
33.76
{"stockData":{"symbol":"688266","market":"SH","secType":"STK","nameCN":"泽璟制药","latestPrice":116.48,"timestamp":1753426800000,"preClose":122.8,"halted":0,"volume":6095612,"delay":0,"changeRate":-0.0515,"floatShares":265000000,"shares":265000000,"eps":-0.4783,"marketStatus":"已收盘","change":-6.32,"latestTime":"07-25 15:00:00","open":122.44,"high":122.5,"low":115.99,"amount":721000000,"amplitude":0.053,"askPrice":116.49,"askSize":6,"bidPrice":116.48,"bidSize":31,"shortable":0,"etf":0,"ttmEps":-0.4783,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753666200000},"marketStatusCode":5,"adr":0,"adjPreClose":122.8,"symbolType":"stock_kcb","openAndCloseTimeList":[[1753407000000,1753414200000],[1753419600000,1753426800000]],"highLimit":135.08,"lowLimit":110.52,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":264708186,"isCdr":false,"pbRate":25.15,"roa":"--","roe":"--","epsLYR":-0.52,"committee":-0.851327,"marketValue":30833000000,"turnoverRate":0.023,"status":1,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2025-07-28。","afterMarket":{"amount":0,"volume":0,"close":116.48,"buyVolume":0,"sellVolume":0,"time":1753428838020,"indexStatus":"已收盘 07-25 15:30:00","preClose":122.8},"floatMarketCap":30833000000},"requestUrl":"/m/hq/s/688266","defaultTab":"news","newsList":[{"id":"2554675576","title":"泽璟制药-U跌5.13% 资金流出叠加板块波动","url":"https://stock-news.laohu8.com/highlight/detail?id=2554675576","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554675576?lang=zh_cn&edition=full","pubTime":"2025-07-25 13:02","pubTimestamp":1753419755,"startTime":"0","endTime":"0","summary":"泽璟制药-U今日股价出现明显调整,截至13点02分,最新价为116.50元/股,跌幅达5.13%。泽璟制药-U近日净流出主要受多重短期因素驱动。截至7月21日,公司主力资金单日净流出超1600万元,而此前三天累计流出超千万元,资金流向呈现高频切换特征。化学制药板块同期剧烈波动,6月末单日资金流出超14亿元,加剧个股震荡。若核心产品放量符合预期,股价或突破当前震荡区间,但研发高压可能加剧波动风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725130242a6c0f079&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725130242a6c0f079&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688266"],"gpt_icon":0},{"id":"2554737477","title":"5款创新药纳入突破性疗法,来自宝济药业、泽璟制药等","url":"https://stock-news.laohu8.com/highlight/detail?id=2554737477","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554737477?lang=zh_cn&edition=full","pubTime":"2025-07-25 10:18","pubTimestamp":1753409939,"startTime":"0","endTime":"0","summary":"根据国家药品监督管理局药品审评中心网站公示,7月以来,已有多款创新药纳入突破性疗法。如7月25日,上海宝济药业股份有限公司注射用KJ103纳入突破性疗法,拟用于抗肾小球基底膜病。资料显示,KJ103是新一代IgG降解酶,它来源于不感染人类的化脓性链球菌的酶,通过宝济药业自主研发设计改构而获得。ZG006 在非人灵长类动物中显示出毒副作用低等良好的安全性特征。业内表示,这几款创新药纳入突破性治疗品种,是医药研发领域的重大进展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725102217971d44ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725102217971d44ca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688266","159992"],"gpt_icon":0},{"id":"2553078322","title":"新事丨罗氏终止TIGIT全部三期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2553078322","media":"健识局","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553078322?lang=zh_cn&edition=full","pubTime":"2025-07-24 20:30","pubTimestamp":1753360205,"startTime":"0","endTime":"0","summary":"在最新的管线中,PD-1联合TIGIT治疗非小细胞肺癌、肝癌的三期临床均已终止。这意味着罗氏针对TIGIT进行的三期临床全部终止。TIGIT靶点的价值是罗氏在2009年最先发现的。当时,罗氏的TIGIT+PD-L1联合疗法的效果曾一鸣惊人,一度被认为是PD-1之后的免疫新星。全球范围内,这几年TIGIT单抗预期快速变化:默沙东、罗氏等药企都已经历多次失败,留给TIGIT靶点成功的希望相当渺茫。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724203245a6bfb977&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724203245a6bfb977&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01801","LU1064131003.USD","LU2328871848.SGD","LU1328615791.USD","LU1997245177.USD","BK0188","600276","MRK","688177","LU1969619763.USD","BK0183","LU2495084118.USD","06160","01276","LU1064130708.USD","BK0012","LU1997244956.HKD","BK0060","LU1997245094.SGD","LU1655091616.SGD","LU2148510915.USD","ONC","688235","688266","LU2488822045.USD","BK0028","LU0405327148.USD","BK0239","LU0405327494.USD","BK0196"],"gpt_icon":1},{"id":"2553575942","title":"券商资管系公募,排名来了!","url":"https://stock-news.laohu8.com/highlight/detail?id=2553575942","media":"中国基金报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553575942?lang=zh_cn&edition=full","pubTime":"2025-07-23 00:06","pubTimestamp":1753200372,"startTime":"0","endTime":"0","summary":"头部券商资管公募管理规模普遍增长Wind数据显示,截至二季度末,共有4家券商资管机构的公募基金资产管理总规模超千亿元。此外,相比于今年一季度末,头部券商资管的公募管理规模普遍增长,东方红资产管理、华泰证券资管规模增长均超200亿元,招商证券资管规模增长33亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723001401a45cdc20&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723001401a45cdc20&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","06160","06990","09969","01276","ONC","600276","688266","688192","688428","688443","BK0239"],"gpt_icon":0},{"id":"2553202447","title":"泽璟制药-U下跌5.02% 盐酸吉卡昔替尼片进展与资金流出共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2553202447","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553202447?lang=zh_cn&edition=full","pubTime":"2025-07-21 09:47","pubTimestamp":1753062440,"startTime":"0","endTime":"0","summary":"泽璟制药-U今日盘中出现明显下跌走势,截至09点46分,最新价为126.78元/股,跌幅达5.02%。资金博弈与事件驱动共振泽璟制药-U近期股价波动与资金面高频切换密切相关。这一资金异动与盐酸吉卡昔替尼片斑秃适应症申请进展、ASCO年会临床数据披露等事件形成共振。商业化进程锚定估值预期泽璟制药长期估值核心在于管线商业化兑现能力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721094721a6b6838f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721094721a6b6838f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688266","BK0239"],"gpt_icon":0},{"id":"2552922490","title":"泽璟制药公布国际专利申请:“取代桥环类抑制剂及其制备方法和应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2552922490","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552922490?lang=zh_cn&edition=full","pubTime":"2025-07-19 04:52","pubTimestamp":1752871946,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示泽璟制药(688266)公布了一项国际专利申请,专利名为“取代桥环类抑制剂及其制备方法和应用”,专利申请号为PCT/CN2025/072109,国际公布日为2025年7月17日。专利详情如下:图片来源:世界知识产权组织(WIPO)今年以来泽璟制药已公布的国际专利申请2个,较去年同期增加了100%。结合公司2024年年报财务数据,2024年公司在研发方面投入了3.88亿元,同比减21.83%。数据来源:企查查以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071900003417.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK0239"],"gpt_icon":0},{"id":"2552536451","title":"广发基金吴兴武旗下广发保健A中报最新持仓,重仓泽璟制药","url":"https://stock-news.laohu8.com/highlight/detail?id=2552536451","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552536451?lang=zh_cn&edition=full","pubTime":"2025-07-18 12:56","pubTimestamp":1752814563,"startTime":"0","endTime":"0","summary":"证券之星消息,7月18日广发基金旗下吴兴武管理的广发医疗保健股票型基金公布中报,近1年净值增长率29.62%。与上一季度相比,该基金前十大重仓股新增百济神州;其中泽璟制药持仓占比9.36%,为该基金第一大重仓股;康龙化成等退出前十大重仓股;详细数据如下:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071800017556.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688266"],"gpt_icon":0},{"id":"2552747871","title":"细胞免疫治疗概念盘中拉升,博济医药涨12.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2552747871","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552747871?lang=zh_cn&edition=full","pubTime":"2025-07-17 09:57","pubTimestamp":1752717476,"startTime":"0","endTime":"0","summary":"07月17日,细胞免疫治疗概念盘中拉升,截至09点57分,细胞免疫治疗概念整体指数上涨1.00%,报968.540点。从个股上来看,该概念的成分股中,博济医药涨12.63%,海南海药、新开源、泽璟制药-U涨幅居前。从资金上来看,截止发稿,细胞免疫治疗概念主力净流入为-1.18亿,其中海南海药受到资金热捧,主力净流入3216.92万;拉长时间线来看,该板块近20日主力资金净流入-23.61亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717095756a44fd4fd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717095756a44fd4fd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688266","BK0239","300404","BK0216"],"gpt_icon":0},{"id":"2552898120","title":"泽璟制药-U股价回落至127元 创新药板块热度持续","url":"https://stock-news.laohu8.com/highlight/detail?id=2552898120","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552898120?lang=zh_cn&edition=full","pubTime":"2025-07-17 01:56","pubTimestamp":1752688583,"startTime":"0","endTime":"0","summary":"截至7月16日收盘,泽璟制药-U股价报127元,较前一交易日下跌2.08%。当日成交量为19927手,成交金额达2.54亿元。该股盘中最高触及130.3元,最低下探至125.7元,振幅为3.55%。泽璟制药-U属于化学制药行业,是一家专注于肿瘤、出血及血液疾病、免疫炎症性疾病等领域的创新驱动型制药企业。根据公开信息显示,泽璟制药-U近期被长城医药产业精选基金纳入前十大重仓股。从资金流向来看,7月16日泽璟制药-U主力资金净流出558.39万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071702035695451f95&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071702035695451f95&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159992","688266","BK0239"],"gpt_icon":0},{"id":"2551143907","title":"中证1000医药卫生指数报12486.30点,前十大权重包含昭衍新药等","url":"https://stock-news.laohu8.com/highlight/detail?id=2551143907","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551143907?lang=zh_cn&edition=full","pubTime":"2025-07-16 15:48","pubTimestamp":1752652097,"startTime":"0","endTime":"0","summary":"金融界7月16日消息,上证指数低开震荡,中证1000医药卫生指数 报12486.30点。数据统计显示,中证1000医药卫生指数近一个月上涨4.34%,近三个月上涨12.39%,年至今上涨16.26%。从中证1000医药卫生指数持仓样本的行业来看,化学药占比35.86%、医疗器械占比19.60%、中药占比17.00%、生物药品占比14.32%、医疗商业与服务占比7.53%、制药与生物科技服务占比5.69%。在样本有特殊事件发生,导致其行业归属发生变更时,将对中证1000行业指数样本进行相应调整。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716155754954490f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716155754954490f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688166","BK0216","688266","000852.SH","000001.SH","603127","688331","399852","159845"],"gpt_icon":0},{"id":"2551119280","title":"科创成长层改革推进 券商系统升级及风险揭示书签署有序展开","url":"https://stock-news.laohu8.com/highlight/detail?id=2551119280","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551119280?lang=zh_cn&edition=full","pubTime":"2025-07-16 11:13","pubTimestamp":1752635582,"startTime":"0","endTime":"0","summary":"上交所方面正组织风险揭示书签署工作,并修订相关指南,新增《科创板科创成长层企业股票投资风险揭示书必备条款》,明确未盈利企业存在的各类投资风险。上交所下发通知要求券商完善适当性管理工作,包括完成风险揭示书签署及系统准备,给予投资者充分阅读时间,并通过多种渠道开展投资者教育。上交所将持续督促券商并开展监督检查。7月14日,上交所举办专题培训会,120家券商330余名相关负责人参会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071611164495444cb2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071611164495444cb2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688327","688343","688221","688322","688176","688382","688192","688302","01877","688373","06160","688197","02402","688220","688316","688266","688702","688512","BK0239","688165","000690.SH","688280","688538","09969","688549","688515","688277","688561","688256","688469","ONC","688443","688387"],"gpt_icon":0},{"id":"2551139731","title":"东吴证券:首次覆盖泽璟制药给予买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2551139731","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551139731?lang=zh_cn&edition=full","pubTime":"2025-07-15 07:35","pubTimestamp":1752536121,"startTime":"0","endTime":"0","summary":"东吴证券股份有限公司朱国广,苏丰,张翀翯近期对泽璟制药进行研究并发布了研究报告《创新进入收获期,ZG006及ZG005均有望成为BIC》,首次覆盖泽璟制药给予买入评级。海外临床获得FDA同意,有望近期入组患者。我们预计公司2025-2027年收入分别为8.18/17.14/28.46亿元,对应当前市值的PS为41/19/12倍,首次覆盖,给予“买入”评级。最新盈利预测明细如下:该股最近90天内共有13家机构给出评级,买入评级12家,增持评级1家;过去90天内机构目标均价为100.35。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071500005628.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","601555"],"gpt_icon":0},{"id":"2551907907","title":"泽璟制药-U涨5.02% 盐酸吉卡昔替尼片新药申请进展及ASCO年会临床数据披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2551907907","media":"智选洞察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551907907?lang=zh_cn&edition=full","pubTime":"2025-07-14 14:23","pubTimestamp":1752474218,"startTime":"0","endTime":"0","summary":"泽璟制药-U股价大幅上涨,最新价126.18元/股,涨跌幅为5.02%。资金博弈与事件驱动共振泽璟制药-U近期股价波动受多重短期因素交织影响。截至7月11日,主力资金连续三日累计净流入875.1万元,其中7月10日单日净流入达7309.9万元,资金活跃度显著提升。事件驱动方面,公司核心产品盐酸吉卡昔替尼片新药申请进展及ASCO年会抗癌药物临床数据披露,引发机构高频交易。盐酸吉卡昔替尼片若成功拓展斑秃适应症,理论增量市场空间达29亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714142339a4491bfc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714142339a4491bfc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688266"],"gpt_icon":0},{"id":"2550173990","title":"中国创新药:出海黄金时代 游到海水变蓝","url":"https://stock-news.laohu8.com/highlight/detail?id=2550173990","media":"中信建投证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550173990?lang=zh_cn&edition=full","pubTime":"2025-07-12 00:00","pubTimestamp":1752249600,"startTime":"0","endTime":"0","summary":"主因中国创新药实力增强,十年创新努力终开花结果。而与此同时,MNC重磅药物专利悬崖即将到来,大多现金充沛,BD迫在眉睫。预计中国出海BD持续蓬勃。免疫与炎症是仅次于肿瘤的第二大疾病领域,已涌现多款百亿美元级别重磅药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712202520a6a57a5e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712202520a6a57a5e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1997244956.HKD","LU1969619763.USD","06160","600276","LU0405327148.USD","BK0028","LU1064131003.USD","LU0405327494.USD","BK0239","LU1655091616.SGD","159992","BK0196","BK0188","688331","LU1997245177.USD","BK0060","LU2495084118.USD","LU1328615791.USD","688266","LU2148510915.USD","BK0012","LU1064130708.USD","BK0183","LU2488822045.USD","LU1997245094.SGD","LU2328871848.SGD"],"gpt_icon":0},{"id":"2550561208","title":"泽璟制药:注射用ZG006纳入突破性治疗品种公示名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2550561208","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550561208?lang=zh_cn&edition=full","pubTime":"2025-07-10 16:55","pubTimestamp":1752137742,"startTime":"0","endTime":"0","summary":"泽璟制药(688266.SH)公告称,公司在研产品注射用ZG006被国家药品监督管理局药品审评中心纳入突破性治疗品种公示名单,适应症为ZG006单药治疗既往经含铂化疗及至少1种其它系统治疗后(三线及以上)复发或进展的晚期小细胞肺癌患者。公示期为2025年7月9日至2025年7月16日,存在被提出异议的风险。该事项对公司近期业绩不会产生重大影响,药品研发周期长、审批环节多、研发投入大,存在不确定性风险。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071000026338.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688266"],"gpt_icon":0},{"id":"2550578616","title":"泽璟制药-U股价报112.60元 科创板百元股医药板块占8席","url":"https://stock-news.laohu8.com/highlight/detail?id=2550578616","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550578616?lang=zh_cn&edition=full","pubTime":"2025-07-09 03:45","pubTimestamp":1752003941,"startTime":"0","endTime":"0","summary":"截至2025年7月8日15时,泽璟制药-U股价报112.60元,较前一交易日下跌2.60元。当日开盘价为114.58元,最高触及117.98元,最低下探至112.20元,成交量为34955手,成交金额达3.99亿元。泽璟制药-U属于科创板医药生物板块企业,专注于肿瘤、出血及血液疾病、免疫炎症性疾病等领域的创新药物研发。公司采用精准小分子药物研发及产业化平台和复杂重组蛋白新药研发及产业化平台双轮驱动模式。数据显示,科创板市场目前共有39只百元股,其中医药生物行业占据8席。在当日交易中,泽璟制药-U主力资金净流出5647.52万元。风险提示:股市有风险,投资需谨慎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/09034551571633.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","BK1515","159938","159982","688266","BK0239","09939","BK1161"],"gpt_icon":0},{"id":"2549308218","title":"肿瘤治疗概念盘中拉升,广生堂涨15.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2549308218","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549308218?lang=zh_cn&edition=full","pubTime":"2025-07-07 09:45","pubTimestamp":1751852719,"startTime":"0","endTime":"0","summary":"07月07日,肿瘤治疗概念盘中拉升,截至09点45分,肿瘤治疗概念整体指数上涨1.02%,报1574.880点。从个股上来看,该概念的成分股中,广生堂涨15.82%,微芯生物、泰恩康等6只股涨幅超过5%。从资金上来看,截止发稿,肿瘤治疗概念主力净流入为-8043.81万,其中泽璟制药-U受到资金热捧,主力净流入4058.63万;拉长时间线来看,该板块近20日主力资金净流入-81.84亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707094519979c71ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707094519979c71ee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688266","300436"],"gpt_icon":0},{"id":"2549308294","title":"泽璟制药-U涨5.34% 利好催化与资金博弈共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2549308294","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549308294?lang=zh_cn&edition=full","pubTime":"2025-07-07 09:30","pubTimestamp":1751851850,"startTime":"0","endTime":"0","summary":"泽璟制药-U今日股价大幅上涨,最新价为121.80元/股,涨幅达5.34%。事件驱动与资金博弈共振泽璟制药-U股价近期波动显著,事件催化与资金流动形成共振。短期扰动因素包括ASCO年会抗癌药物数据披露及盐酸吉卡昔替尼片NDA进展,机构调研后引发高频博弈。商业化进程决定估值天花板长期来看,泽璟制药的核心逻辑在于创新药商业化兑现能力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707093507a43aacb9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707093507a43aacb9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688266"],"gpt_icon":0},{"id":"2548876295","title":"泽璟制药:截至2025年3月31日公司股东户数为7,533户","url":"https://stock-news.laohu8.com/highlight/detail?id=2548876295","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548876295?lang=zh_cn&edition=full","pubTime":"2025-07-03 16:21","pubTimestamp":1751530866,"startTime":"0","endTime":"0","summary":"证券之星消息,泽璟制药(688266)07月03日在投资者关系平台上答复投资者关心的问题。投资者提问:截止今天股东人数多少?泽璟制药回复:尊敬的投资者,您好!根据信息披露公平性原则,公司将按照相关规定,在定期报告中面向所有投资者统一披露截至报告期末的股东户数(截至2025年3月31日公司股东户数为7,533户)。股东如确需查阅其他时点的股东人数,请携带股东证明、本人身份证原件等材料前往公司进行现场查询,具体可拨打公司投资者热线电话咨询。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070300025508.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688266"],"gpt_icon":0},{"id":"2548025846","title":"泽璟制药-U涨5.11%创短期新高 资金博弈与事件驱动共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2548025846","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548025846?lang=zh_cn&edition=full","pubTime":"2025-07-01 10:57","pubTimestamp":1751338624,"startTime":"0","endTime":"0","summary":"泽璟制药-U今日股价大幅上涨,截至10点56分,最新价为113.00元/股,涨幅达5.11%。资金博弈加剧股价波动泽璟制药-U近期净流出与资金面剧烈波动密切相关。事件驱动成为短期焦点:诺鼎资产等机构对盐酸吉卡昔替尼片NDA进展的密集调研,叠加ASCO年会抗癌药物数据披露,引发交易型资金频繁进出。管线兑现能力决定估值中枢泽璟制药长期估值重构取决于创新药商业化进程。盐酸吉卡昔替尼片若成功拓展至斑秃适应症,理论增量市场空间达29亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701105713a7276120&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701105713a7276120&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688266","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1753518102835,"stockEarnings":[{"period":"1week","weight":-0.1274},{"period":"1month","weight":0.0158},{"period":"3month","weight":0.1558},{"period":"6month","weight":0.763},{"period":"1year","weight":1.3347},{"period":"ytd","weight":0.8694}],"compareEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":0.0398},{"period":"3month","weight":0.0906},{"period":"6month","weight":0.1048},{"period":"1year","weight":0.2449},{"period":"ytd","weight":0.0722}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"苏州泽璟生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"7533人(较上一季度减少9.75%)","perCapita":"35139股","listingDate":"2020-01-23","address":"江苏省苏州市昆山市玉山镇晨丰路209号","registeredCapital":"26470万元","survey":" 苏州泽璟生物制药股份有限公司的主营业务是化学新药及生物新药的研发、生产及销售。公司的主要产品是药品。","listedPrice":33.76},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泽璟制药(688266)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泽璟制药(688266)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泽璟制药,688266,泽璟制药股票,泽璟制药股票老虎,泽璟制药股票老虎国际,泽璟制药行情,泽璟制药股票行情,泽璟制药股价,泽璟制药股市,泽璟制药股票价格,泽璟制药股票交易,泽璟制药股票购买,泽璟制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泽璟制药(688266)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泽璟制药(688266)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}